Cardinal Health (CAH)
(Delayed Data from NYSE)
$94.10 USD
-0.36 (-0.38%)
Updated Jul 12, 2024 03:59 PM ET
After-Market: $94.12 +0.02 (0.02%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$94.10 USD
-0.36 (-0.38%)
Updated Jul 12, 2024 03:59 PM ET
After-Market: $94.12 +0.02 (0.02%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
Zacks News
3 Medical Device Stocks With Solid Dividend Yield: CAH & Others
by Indrajit Bandyopadhyay
Here we pick three medical device stocks, Cardinal Health (CAH), Baxter International (BAX) and Fresenius Medical Care (FMS), with a solid five-year dividend growth history.
Quest Diagnostics (DGX) Gains From New Alliances Amid FX Woes
by Zacks Equity Research
Quest Diagnostics' (DGX) recent acquisition of New York-Presbyterian's outreach assets adds to volume growth within Physician Lab Services.
Align (ALGN) Gains From New Launches, Strategic Partnerships
by Zacks Equity Research
Align Technology (ALGN) has well-established relationships with many DSOs, especially in the United States.
Here's Why You Should Retain QIAGEN (QGEN) Stock for Now
by Zacks Equity Research
Investors are optimistic about QIAGEN's (QGEN) growth in the molecular diagnostics business and the latest acquisition.
Baxter's (BAX) New Launch to Enable Earlier Treatment of Eye
by Zacks Equity Research
Baxter's (BAX) latest offering is likely to enable a more digitally-connected primary care examination and support faster diagnosis for earlier treatment of eye conditions.
Abbott (ABT) Q3 Earnings and Revenues Surpass, Margins Dip
by Zacks Equity Research
Abbott (ABT) reports solid underlying base business performance in the third quarter of 2023.
Here's Why You Should Add DaVita (DVA) Stock to Your Portfolio
by Zacks Equity Research
DaVita's (DVA) strength in its DaVita Kidney Care raises optimism about the stock.
STERIS' (STE) Improved Volume, New Buyouts Drive Growth
by Zacks Equity Research
On the capital equipment side for STERIS (STE), the easing of supply-chain issues and reduced lead times are boosting shipments.
PetMeds (PETS) to Advance Pet Care With New Collaboration
by Zacks Equity Research
PetMeds (PETS) is positioning itself more firmly in the field of pet health and wellness as a result of its established reputation in the pet pharmaceutical industry.
PacBio's (PACB) New Offering to Boost WGS Data Analysis
by Zacks Equity Research
PacBio's (PACB) latest software pipeline is likely to provide standardization to HiFi WGS analysis.
3 Reasons to Add Integer Holdings (ITGR) Stock to Your Portfolio
by Zacks Equity Research
Integer Holdings' (ITGR) research and product development activities and a solid foothold in the broader MedTech space raise optimism about the stock.
Orthofix (OFIX) Secures FDA 510k Clearance for OsteoCove Graft
by Zacks Equity Research
Orthofix (OFIX) announces the full commercial availability of the OsteoCove synthetic graft after gaining the FDA's nod.
Here's Why You Should Buy Edward Lifesciences (EW) Stock Now
by Zacks Equity Research
Investors remain optimistic about Edward Lifesciences (EW) on the strength of the Critical Care business and TAVR sales.
Zacks.com featured highlights Rev Group, CVR Energy, Cardinal Health, Commercial Vehicle and Archer Daniels Midland
by Zacks Equity Research
Rev Group, CVR Energy, Cardinal Health, Commercial Vehicle and Archer Daniels Midland have been highlighted in this Screen of The Week article.
Here's Why You Should Invest in Insulet (PODD) Stock for Now
by Zacks Equity Research
Investors are optimistic about Insulet (PODD) on continued expansion in Omnipod's market access.
Alcon (ALC) Stock Up 9.7% YTD: Will the Rally Continue?
by Zacks Equity Research
Alcon (ALC) continues gaining from the company's diverse portfolio, incremental innovation, and new product launches.
5 Stocks That Brokers Favor Despite the Ongoing Uncertainty
by Maharathi Basu
We believe that stocks like Rev Group (REVG), CVR Energy (CVI), Cardinal Health (CAH), Commercial Vehicle Group (CVGI) and Archer Daniels (ADM) should be on an investor's watchlist.
Boston Scientific's (BSX) Wavewriter Alpha SCS Gets FDA's Nod
by Zacks Equity Research
Boston Scientific (BSX) receives the FDA's nod for an expanded indication of Wavewriter SCS Systems.
Here's Why Investors Should Retain Thermo Fisher (TMO) Stock
by Zacks Equity Research
Investors continue to be optimistic about Thermo Fisher (TMO) due to its impressive acquisition deals and end-market strength.
Globus Medical (GMED) Gains From NuVasive Buyout, Innovation
by Zacks Equity Research
Globus Medical (GMED) is particularly seeing notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.
Labcorp (LH) Launches Biomarker Test for Alzheimer's Disease
by Zacks Equity Research
Labcorp's (LH) new test, ATN Profile, is likely to accelerate the path to the diagnosis of Alzheimer's disease.
Alcon (ALC) Gains From Growing Market Demand, New Launches
by Zacks Equity Research
Within Vision Care, Alcon (ALC) is registering solid growth, banking on strong sales of its contact lenses and ocular health products.
ZimVie (ZIMV) Progresses in Dental Space With Biotivity Launch
by Zacks Equity Research
ZimVie's (ZIMV) Biotivity A/C Plus Membrane is a barrier membrane that contains an array of growth factors.
Hologic (HOLX) to Elevate OB-GYN Training With New Partnerships
by Zacks Equity Research
Hologic's (HOLX) collaboration with AAGL and Inovus Medical is likely to optimize OB-GYN training for minimally invasive surgeries.
Haemonetics (HAE) Announces Agreement to Acquire OpSens
by Zacks Equity Research
Haemonetics' (HAE) acquisition of OpSens will expand its leadership in the interventional cardiology market.